Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin plus nivolumab versus nivolumab in previously untreated unresectable or metastatic melanoma
NL-OMON52577Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bempegaldesleukin and nivolumab in melanoma, sponsored by Bristol Myers Squibb. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Dec 2020; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON52577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52577.